Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:DERMNASDAQ:FATENASDAQ:HOWL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.11+15.0%$1.74$1.43▼$4.37$183.75M1.57147,903 shs246,251 shsDERMJourney Medical$6.95+8.9%$6.99$3.54▼$8.25$148.63M0.8782,353 shs113,882 shsFATEFate Therapeutics$1.17+2.6%$1.23$0.66▼$5.92$130.65M2.232.20 million shs1.32 million shsHOWLWerewolf Therapeutics$1.25$1.09$0.60▼$4.18$56.09M0.65441,445 shs477,897 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune+15.03%+9.64%+24.56%+5.78%-49.28%DERMJourney Medical+8.93%+10.14%-0.71%+13.19%+40.97%FATEFate Therapeutics+2.63%-2.50%+0.86%+36.99%-69.53%HOWLWerewolf Therapeutics0.00%+3.31%+8.70%+21.36%-52.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune1.9213 of 5 stars3.53.00.00.00.60.80.6DERMJourney Medical2.4103 of 5 stars3.62.00.00.02.01.70.6FATEFate Therapeutics3.9971 of 5 stars3.13.00.04.71.91.70.6HOWLWerewolf Therapeutics3.1202 of 5 stars3.53.00.00.00.65.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00470.07% UpsideDERMJourney Medical 3.20Buy$9.8842.09% UpsideFATEFate Therapeutics 2.13Hold$3.83227.64% UpsideHOWLWerewolf Therapeutics 3.00Buy$8.33566.67% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, ACIU, DERM, and FATE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.005/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M6.81N/AN/A$1.29 per share1.63DERMJourney Medical$56.13M2.88N/AN/A$0.91 per share7.64FATEFate Therapeutics$13.63M9.84N/AN/A$2.80 per share0.42HOWLWerewolf Therapeutics$1.14M49.07N/AN/A$1.65 per share0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)DERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)Latest HOWL, ACIU, DERM, and FATE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.531.53DERMJourney Medical1.071.341.03FATEFate TherapeuticsN/A8.818.81HOWLWerewolf Therapeutics0.468.098.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%DERMJourney Medical7.25%FATEFate Therapeutics97.54%HOWLWerewolf Therapeutics64.84%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%DERMJourney Medical15.03%FATEFate Therapeutics5.51%HOWLWerewolf Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableDERMJourney Medical9023.30 million19.80 millionN/AFATEFate Therapeutics550114.60 million108.29 millionOptionableHOWLWerewolf Therapeutics4044.87 million34.28 millionOptionableHOWL, ACIU, DERM, and FATE HeadlinesRecent News About These CompaniesWerewolf Therapeutics to Participate in the BIO International ConventionJune 12, 2025 | globenewswire.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLCJune 6, 2025 | marketbeat.comWerewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should KnowMay 29, 2025 | zacks.comWerewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWerewolf Therapeutics’ SWOT analysis: innovative platform drives stock potentialMay 24, 2025 | investing.comWerewolf Therapeutics Stock Price, Quotes and ForecastsMay 20, 2025 | benzinga.comHonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124May 20, 2025 | globenewswire.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Acquires $159,288.22 in StockMay 15, 2025 | insidertrades.comWerewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development SummitMay 13, 2025 | globenewswire.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.deWerewolf Therapeutics Announces Q1 2025 Financial ResultsMay 9, 2025 | msn.comWerewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWerewolf Therapeutics reports progress on IBD treatmentMay 6, 2025 | investing.comWerewolf Therapeutics to Participate in Upcoming Investor ConferencesMay 5, 2025 | globenewswire.comListening to the Desert’s “Werewolf Mouse” Reveals the Complex World of BioacousticsMay 1, 2025 | marfapublicradio.orgEarnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to DeclineApril 25, 2025 | zacks.comWerewolf Therapeutics appoints Bloom as Chief Business OfficerApril 17, 2025 | markets.businessinsider.comWerewolf Therapeutics Appoints Steven Bloom as Chief Business OfficerApril 17, 2025 | quiverquant.comWerewolf Therapeutics Appoints Steven Bloom as Chief Business OfficerApril 17, 2025 | globenewswire.comWatch: First dire wolf’s howl for 10,000 years after scientists bring extinct species ‘back to life’April 8, 2025 | msn.comWerewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOWL, ACIU, DERM, and FATE Company DescriptionsAC Immune NASDAQ:ACIU$2.10 +0.28 (+15.03%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.15 +0.04 (+2.14%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Journey Medical NASDAQ:DERM$6.95 +0.57 (+8.93%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$6.95 0.00 (0.00%) As of 06/24/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Fate Therapeutics NASDAQ:FATE$1.17 +0.03 (+2.63%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.43%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Werewolf Therapeutics NASDAQ:HOWL$1.25 0.00 (0.00%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.23 -0.02 (-1.52%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
